Literature DB >> 17568038

ERCC1 and non-small-cell lung cancer.

Laura J Niedernhofer, Nikhil Bhagwat, Richard D Wood.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17568038     DOI： 10.1056/NEJMc070742

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  34 in total

Review 1.  The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.

Authors:  Vesna Bišof; Matea Zajc Petranović; Zoran Rakušić; Kristina Ruža Samardžić; Antonio Juretić
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-07-16       Impact factor: 2.503

Review 2.  Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures.

Authors:  Simona Carnio; Silvia Novello; Mauro Papotti; Marco Loiacono; Giorgio Vittorio Scagliotti
Journal:  Transl Lung Cancer Res       Date:  2013-10

3.  The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.

Authors:  Brianna Barsanti-Innes; Spencer Phillips Hey; Jonathan Kimmelman
Journal:  Oncologist       Date:  2016-10-24

4.  XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.

Authors:  Alec Vaezi; Xiaozhe Wang; Shama Buch; William Gooding; Lin Wang; Raja R Seethala; David T Weaver; Alan D D'Andrea; Athanassios Argiris; Marjorie Romkes; Laura J Niedernhofer; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

5.  Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.

Authors:  Julie A Deloia; Nikhil R Bhagwat; Kathleen M Darcy; Mary Strange; Chunquio Tian; Kevin Nuttall; Thomas C Krivak; Laura J Niedernhofer
Journal:  Gynecol Oncol       Date:  2012-05-16       Impact factor: 5.482

6.  ERCC1, XPF and XPA-locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma.

Authors:  Sebastian Prochnow; W Wilczak; V Bosch; T S Clauditz; A Muenscher
Journal:  Clin Oral Investig       Date:  2018-11-29       Impact factor: 3.573

Review 7.  The ERCC1 and ERCC4 (XPF) genes and gene products.

Authors:  Mandira Manandhar; Karen S Boulware; Richard D Wood
Journal:  Gene       Date:  2015-06-12       Impact factor: 3.688

8.  Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Authors:  Daniel C Christoph; Bernadette Reyna Asuncion; Celine Mascaux; Cindy Tran; Xian Lu; Murry W Wynes; Thomas C Gauler; Jeremias Wohlschlaeger; Dirk Theegarten; Volker Neumann; Rodrigo Hepp; Stefan Welter; Georgios Stamatis; Andrea Tannapfel; Martin Schuler; Wilfried E Eberhardt; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

Review 9.  DNA repair targeted therapy: The past or future of cancer treatment?

Authors:  Navnath S Gavande; Pamela S VanderVere-Carozza; Hilary D Hinshaw; Shadia I Jalal; Catherine R Sears; Katherine S Pawelczak; John J Turchi
Journal:  Pharmacol Ther       Date:  2016-02-16       Impact factor: 12.310

10.  Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer.

Authors:  Emre Tepeli; Vildan Caner; Nur Büyükpınarbaşılı; G Ozan Çetin; Füsun Düzcan; Levent Elmas; Gülseren Bağcı
Journal:  Mol Biol Rep       Date:  2011-05-07       Impact factor: 2.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.